Mosunetuzumab Expands Promise in Mantle Cell and Marginal Zone Lymphoma: Phase II Results

Hematologic Malignancies, Mantle Cell Lymphoma, Marginal Zone Lymphoma /

Mosunetuzumab showed early promise for improving outcomes in two key lymphoma subtypes with 88% response rates in MCL.

Mosunetuzumab Expands Promise in Mantle Cell and Marginal Zone Lymphoma: Phase II Results Read More »